Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer
- Conditions
- First Posted Date
- 2006-08-30
- Last Posted Date
- 2014-06-03
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT00369889
- Locations
- 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 15
- Registration Number
- NCT00369512
- Locations
- 🇺🇸
University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- Nasser Hanna, M.D.
- Target Recruit Count
- 25
- Registration Number
- NCT00367601
- Locations
- 🇺🇸
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
🇺🇸Community Regional Cancer Center, Indianapolis, Indiana, United States
🇺🇸Cancer Care Center of Southern Indiana, Bloomington, Indiana, United States
Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT00366457
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 1574
- Registration Number
- NCT00364351
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
- Conditions
- Interventions
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00360360
- Locations
- 🇺🇸
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸Graves-Gilbert Clinic, Bowling Green, Kentucky, United States
🇺🇸Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2017-03-23
- Target Recruit Count
- 8
- Registration Number
- NCT00351039
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2016-01-15
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 760
- Registration Number
- NCT00349219
- Locations
- 🇨🇦
Kingston Regional Cancer Centre, Kingston, Ontario, Canada
🇮🇹Ospedale S. Vincenzo di Taormina, Taormina, ME, Italy
🇮🇹Ospedale Cardinal Massaia, Asti, Italy
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene
- First Posted Date
- 2006-06-21
- Last Posted Date
- 2006-06-21
- Lead Sponsor
- AZ-VUB
- Target Recruit Count
- 40
- Registration Number
- NCT00339586
- Locations
- 🇧🇪
AZ VUB, Jette, Belgium
A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer
- First Posted Date
- 2006-06-14
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Herbert J. Zeh, III MD, FACS
- Target Recruit Count
- 25
- Registration Number
- NCT00336700
- Locations
- 🇺🇸
UPMC Cancer Centers Network, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.